glp-1 news nov 2025 Pipeline Update: August - Prime Therapeutics ISPOR 2025: Exploring reasons for

Why does medication pricing vary by pharmacy

For some time now I've been trying to educate physicians that nobody should be prescribed a weight loss medication like this without a co-requsite referral to a nutritionist

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

the glucagon arm additionally nudges energy expenditure and hepatic fat handling upward

This higher concentration means a smaller injection volume for the same dose, and it also changes how the insulin absorbs into the body, creating a flatter, more prolonged activity profile that can last up to 36 hours

Zepbound for obstructive sleep apnea FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in obese adults